SCHEMBL991622

SCHEMBL991622

CNCCc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.58
KCNH2 Q12809 2/20 0.55
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
CA12 O43570 1/20 0.53
CA4 P22748 1/20 0.53
TAAR1 Q96RJ0 3/20 0.52
ALDH1A1 P00352 2/20 0.52
LOXL2 Q9Y4K0 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TMEM97 Q5BJF2 1/20 0.52
SIGMAR1 Q99720 1/20 0.52
KCNJ1 P48048 1/20 0.51
RAB9A P51151 2/20 0.51
MAPT P10636 2/20 0.51
NPC1 O15118 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3922824 0.98 TSHR (0.56) TSHRKCNH2CA1CA2MEN1
SCHEMBL9386876 0.89 TSHR (0.55) TSHRKCNH2CA1CA2MEN1
SCHEMBL28771841 0.87 KCNH2 (0.72) KCNH2ALDH1A1RAB9AMAPT
SCHEMBL11239026 0.87 L3MBTL1 (0.55) TSHRKCNH2MEN1KMT2AALDH1A1
SCHEMBL9628053 0.84 KCNH2 (0.73) TSHRKCNH2CA1CA2MEN1
SCHEMBL12693810 0.82 TSHR (0.60) TSHRKCNH2CA1CA2MEN1
Dimethylamine SCHEMBL8780943 0.82 KCNH2 (0.57) TSHRKCNH2CA1CA2MEN1
SCHEMBL8780928 0.81 KCNH2 (0.60) TSHRKCNH2CA1CA2MEN1
SCHEMBL3292782 0.81 TSHR (0.75) TSHRKCNH2ALDH1A1LOXL2HSD17B10
SCHEMBL14342284 0.81 TMEM97 (0.57) TSHRMEN1KMT2ATAAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-04-10 US disclosed
EP-4486390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF Terremoto Biosciences, Inc (US) 2025-01-08 EP disclosed
US-20240025846-A1 ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS ACAD PHARMACEUTICALS INC (US) 2024-01-25 US disclosed
US-11826350-B2 Proline-based neuropeptide FF receptor modulators RESEARCH TRIANGLE INSTITUTE (US) 2023-11-28 US disclosed
CN-116964044-A Acetamido-phenyltetrazole derivatives and methods of use thereof 希华医药有限公司 2023-10-27 CN disclosed
WO-2023168291-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-09-07 WO disclosed
WO-2023168291-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2023-09-07 WO disclosed
US-11731938-B2 Ultra short acting anti-arrhythmic agents ACADEMIC PHARMACEUTICALS INC (US) 2023-08-22 US disclosed
EP-4225747-A1 ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME Athenex, Inc. (US) 2023-08-16 EP disclosed
US-20230227418-A1 USP9X INHIBITORS ProDeg, LLC 2023-07-20 US disclosed
US-4959366-A Anti-arrhythmic agents PFIZER INC. (US) 1990-09-25 US disclosed
US-4956382-A TERTIARY AMINE HETEROCYCLIC SULFONAMIDES PFIZER INC. (US) 1990-09-11 US disclosed
EP-0281254-B1 ANTIARRYTHMIC AGENTS Pfizer Limited (GB) 1990-01-17 EP disclosed
EP-0286278-A1 Indanamine derivatives useful as antiarrhythmic agents Pfizer Limited (GB) 1988-10-12 EP disclosed
EP-0281254-A1 Antiarrythmic agents Pfizer Limited (GB) 1988-09-07 EP disclosed
EP-0259782-A1 Naphthalene and indane derivatives, medicaments containing these compounds and processes for their preparation Dr. Karl Thomae GmbH (DE) 1988-03-16 EP disclosed
EP-0245997-A2 N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor Pfizer Limited (GB) 1987-11-19 EP disclosed
EP-0065229-B1 BENZAZEPINES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS Dr. Karl Thomae GmbH (DE) 1985-08-07 EP disclosed
US-4490369-A HYPOTENSIVE, BRRADYCARDIAL DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1984-12-25 US disclosed
EP-0065229-A1 Benzazepines, process for their preparation and their application as pharmaceutical preparations Dr. Karl Thomae GmbH (DE) 1982-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT1S1, AKT2 TSHR 3503/4885KCNH2 4380/4885CA1 3828/4885
US-11731938-B2 Ultra short acting anti-arrhythmic agents CACNA1G, SCN5A, CACNA1F TSHR 3618/4885KCNH2 51/4885CA1 4090/4885
US-20240025846-A1 ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS CACNA1G, SCN5A, CACNA1F TSHR 3618/4885KCNH2 51/4885CA1 4090/4885
US-11826350-B2 Proline-based neuropeptide FF receptor modulators NPFFR1, NPFFR2, NPBWR1 TSHR 126/4885KCNH2 4373/4885CA1 3182/4885
US-20230227418-A1 USP9X INHIBITORS USP9X, USP19, USP39 TSHR 3754/4885KCNH2 4394/4885CA1 2174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.